2022 annual financial data
Metagenomi Therapeutics 2022 Operating margin
Metagenomi Therapeutics 2022 operating margin with verified reported values.
Direct answer
Operating margin was -259.53%.
Operating income was -44,640,000 USD and net income was -43,593,000 USD.
Operating cash flow was 29,724,000 USD.
Get free Metagenomi Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 17,200,000 USD
- Operating income
- -44,640,000 USD
- Net income
- -43,593,000 USD
- Operating cash flow
- 29,724,000 USD